Abstract
Recent studies have demonstrated that exosome therapy can promote the recovery of ovaries in premature ovarian failure (POF) models, which may aid in fertility restoration. This study aimed to investigate the therapeutic efficacy of exosomes derived from menstrual blood-derived mesenchymal stem cells (MenSCs-Exos) in a POF rat model, exploring its underlying mechanisms and detecting the optimal effective therapeutic dose. A POF model was established by an alkylating agent cyclophosphamide (CTX). All POF rats were divided into four groups (eight rats per group) and received a single intervention via the tail vein: phosphate-buffered saline (PBS), low-dose MenSCs-Exos (0.5 mL), middle-dose MenSCs-Exos (1 mL), high-dose MenSCs-Exos (2.0 mL). The concentration of MenSCs-Exos was 1 × 109 particles/mL. Serum was collected from the tail vein before CTX injection and on the 14th day after MenSCs-Exos treatment to measure the serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), anti-Müllerian hormone (AMH), and estradiol (E2) via ELISA. The ovarian pathology and follicle counts were examined by H&E. The protein expression and concentration of B-cell lymphoma-2(Bcl-2) and Bcl-2 associated X protein (Bax) in ovarian tissue were examined by western blot and ELISA. Rats in the middle- and high-dose MenSCs-Exos groups recovered their physical condition after treatment, and their body weight was significantly higher than that of the placebo group but lower than that of the control group, respectively ( P < 0.05). Compared to the placebo group, serum E2 and AMH levels were significantly increased, while serum FSH and LH levels were decreased (P < 0.05). MenSCs-Exos treatment also improved ovarian tissue morphology, and the number of follicles at all stages was markedly increased compared with those in the placebo group ( P < 0.05). In addition, the expression of anti-apoptotic Bcl-2 protein was significantly up-regulated and the expression of pro-apoptotic Bax protein was markedly inhibited after treatment, and the Bcl-2/Bax ratio was also significantly increased ( P < 0.05). Finally, the middle-dose achieved optimal therapeutic effect among the three MenSCs-Exos groups, as the low-dose achieved a less effective outcome and the high-dose exerted no additional therapeutic effects. MenSCs-Exos transplantation could effectively restore ovarian function and promote ovarian regeneration in Chemotherapy-induced POF model, whose mechanism is mainly associated with the regulation of apoptotic-related proteins expression. Additionally, the effective dose is middle-dose MenSCs-Exos (1 mL) or 1 × 109 particles in POF rats. Nevertheless, all these findings require further clinical validation in human models.
Data availability
The data that support the findings of this study are available from the corresponding author, Zhen-Yu Xu, upon reasonable request.
References
Coulam, C. B., Adamson, S. C. & Annegers, J. F. Incidence of premature ovarian failure. Obstet. Gynecol. 67(4), 604–606 (1986).
Jankowska, K. Premature ovarian failure. Prz. Menopauzalny 6(2), 51–56 (2017).
Van-Dorp, W. et al. Reproductive function and outcomes in female survivors of childhood, adolescent, and young adult cancer: A review. J. Clin. Oncol. 36(21), 2169–2180 (2018).
Hickman, L. C., Llarena, N. C., Valentine, L. N., Liu, X. & Falcone, T. Preservation of gonadal function in women undergoing chemotherapy: A systematic review and meta-analysis of the potential role for gonadotropin-releasing hormone agonists. J. Assist. Reprod. Genet. 35(4), 571–581. https://doi.org/10.1007/s10815-018-1128-2 (2018).
Santamaria, X. et al. Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman’s syndrome and endometrial atrophy: A pilot cohort study. Hum. Reprod. 31(5), 1087–1096 (2016).
Fu, Y. X., Ji, J., Shan, F., Li, J. & Hu, R. Human mesenchymal stem cell treatment of premature ovarian failure: New challenges and opportunities. Stem Cell Res. Ther. 12(1), 161 (2021).
Sheikhansari, G., Aghebati-Maleki, L., Nouri, M., Jadidi-Niaragh, F. & Yousefi, M. Current approaches for the treatment of premature ovarian failure with stem cell therapy. Biomed. Pharmacother. 102, 254–262 (2018).
Zafardoust, S. et al. Intraovarian administration of autologous menstrual blood derived-mesenchymal stromal cells in women with premature ovarian failure. Arch. Med. Res. 54(2), 135–144 (2023).
Huang-Doran, I., Zhang, C. Y. & Vidal-Puig, A. Extracellular vesicles: Novel mediators of cell communication in metabolic disease. Trends Endocrinol Meta b 28(1), 3–18 (2017).
Park, H. S. et al. Comparison of the therapeutic effects between stem cells and exosomes in primary ovarian insufficiency: As promising as cells but different persistency and dosage. Stem Cell Res. Ther. 14(1), 165 (2023).
Van Delen, M., Derdelinckx, J., Wouters, K., Nelissen, I. & Cools, N. A systematic review and meta-analysis of clinical trials assessing safety and efficacy of human extracellular vesicle-based therapy. J. Extracell. Vesicles 13(7), e12458. https://doi.org/10.1002/jev2.12458 (2024).
Ding, C. et al. Exosomal miRNA-17-5p derived from human umbilical cord mesenchymal stem cells improves ovarian function in premature ovarian insufficiency by regulating SIRT7. Stem Cells 38(9), 1137–1148 (2020).
Yang, M. et al. Bone marrow mesenchymal stem cell-derived exosomal miR-144-5p improves rat ovarian function after chemotherapy-induced ovarian failure by targeting PTEN. Lab. Invest. 100(3), 342–352 (2020).
Meng, X. et al. Endometrial regenerative cells: A novel stem cell population. J. Transl. Med. 5, 57 (2007).
Bozorgmehr, M. et al. Endometrial and menstrual blood mesenchymal stem/stromal cells: Biological properties and clinical application. Front. Cell Dev. Biol. 8, 497 (2020).
Chen, Z. et al. Identification of specific markers for human pluripotent stem cell-derived small extracellular vesicles. J. Extracell. Vesicles. 13(2), e12409 (2024).
Li, J. et al. Cistanche deserticola polysaccharides protect against cyclophosphamide-induced premature ovarian failure in mice by regulating the JAK-STAT pathway. J. Ethnopharmacol. 349, 119971. https://doi.org/10.1016/j.jep.2025.119971 (2025).
Song, D. et al. Human umbilical cord mesenchymal stem cells therapy in cyclophosphamide-induced premature ovarian failure rat model. Biomed Res Int 2016, 2517514 (2016).
Zhang, S., Yahaya, B. H., Pan, Y., Liu, Y. & Lin, J. Menstrual blood-derived endometrial stem cell, a unique and promising alternative in the stem cell-based therapy for chemotherapy-induced premature ovarian insufficiency. Stem Cell Res. Ther. 14(1), 327 (2023).
Lai, D. et al. Human endometrial mesenchymal stem cells restore ovarian function through improving the renewal of germline stem cells in a mouse model of premature ovarian failure. J. Transl. Med. 13, 155 (2015).
Zhang, Z., Shi, C. & Wang, Z. The physiological functions and therapeutic potential of exosomes during the development and treatment of polycystic ovary syndrome. Front. Physiol. 14, 1279469 (2023).
Hade, M. D., Suire, C. N. & Suo, Z. Mesenchymal stem cell-derived exosomes: Applications in regenerative medicine. Cells 10(8), 1959 (2021).
Bagno, L., Hatzistergos, K. E., Balkan, W. & Hare, J. M. Mesenchymal stem cell-based therapy for cardiovascular disease: Progress and challenges. Mol. Ther. 26(7), 1610–1623 (2018).
Vizoso, F. J., Eiro, N., Cid, S., Schneider, J. & Perez-Fernandez, R. Mesenchymal stem cell secretome: Toward cell-free therapeutic strategies in regenerative medicine. Int. J. Mol. Sci. 18(9), 1852 (2017).
Zhang, J., Yin, H., Jiang, H., Du, X. & Yang, Z. The protective effects of human umbilical cord mesenchymal stem cell-derived extracellular vesicles on cisplatin-damaged granulosa cells. Taiwan J. Obstet. Gynecol. 59(4), 527–533 (2020).
Liu, C. et al. Extracellular vesicles derived from mesenchymal stem cells recover fertility of premature ovarian insufficiency mice and the effects on their offspring. Cell Transplant 29, 963689720923575 (2020).
Zhang, S. et al. Concentrated exosomes from menstrual blood-derived stromal cells improves ovarian activity in a rat model of premature ovarian insufficiency. Stem Cell Res. Ther. 12(1), 178 (2021).
Plowchalk, D. R. & Mattison, D. R. Reproductive toxicity of cyclophosphamide in the C57BL/6N mouse: 1. Effects on ovarian structure and function. Reprod. Toxicol. 6(5), 411–421 (1992).
Sun, Y. et al. 2, 5-Hexanedione induces human ovarian granulosa cell apoptosis through BCL-2, BAX, and CASPASE-3 signaling pathways. Arch. Toxicol. 86(2), 205–215 (2012).
Sasson, R. & Amsterdam, A. Stimulation of apoptosis in human granulosa cells from in vitro fertilization patients and its prevention by dexamethasone: Involvement of cell contacts and bcl-2 expression. J. Clin. Endocrinol. Metab. 87(7), 3441–3451 (2002).
Liu, Y. et al. Ethanol promotes apoptosis in rat ovarian granulosa cells via the Bcl-2 family dependent intrinsic apoptotic pathway. Cell Mol Biol (Noisy-le-grand) 64(1), 118–125 (2018).
Sun, L. et al. Exosomes derived from human umbilical cord mesenchymal stem cells protect against cisplatin-induced ovarian granulosa cell stress and apoptosis in vitro. Sci. Rep. 7(1), 2552 (2017).
Liu, M. et al. Small extracellular vesicles derived from embryonic stem cells restore ovarian function of premature ovarian failure through PI3K/AKT signaling pathway. Stem Cell Res. Ther. 11(1), 3 (2020).
Acknowledgements
We are grateful to Yong He for animal experiment technical guidance.
Funding
This study was supported by grants from the National Key R&D Program of China grant (No. 2022YFC2304405 and 2022YFA1105603); Zhejiang Provincial Key Research and Development Program (No. 2019C03015); Hangzhou Health Science and Technology Plan Project(No. B20220020); Medical and Health Technology Plan Project in Gongshu District, Hangzhou, Zhejiang Province(No. A202208); Zhejiang Province Traditional Chinese Medicine Technology Plan Project(No. 2023ZL591); the Key laboratory& Women’s Hospital, Zhejiang University School of Medicine (No. ZDFY2022-RG-4). The funders played no role in the design and implementation of the study, data analysis, drafting the manuscript or the decision to submit the manuscript for publication.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. XY CHENG, YQ W and LC conducted the experiments; ZY XU, LQ YANG and LY XU prepared the exosomes; MJ LIU performed blot and ELISA; TZ conducted HE staining and histological analysis; YY WANG and GH YANG collected and analyzed the data; YG WANG provided technical and writing guidance; XY CHENG and ZY XU prepared the manuscript for publication and reviewed the draft of the manuscript. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Cheng, X., Wu, Y., Cheng, L. et al. Menstrual blood-derived stem cell exosomes improve ovarian function in chemotherapy-Induced POF rats via apoptosis regulation. Sci Rep (2026). https://doi.org/10.1038/s41598-026-43562-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-43562-0
